NEW YORK, NY--(Marketwire - Jan 25, 2012) - The medical device sector has been seeing increased investor interest over the last year. According to a recent report from Dow Jones, venture investments held strong across healthcare in 2011, with medical devices finishing a close second to biopharmaceuticals in dollars invested. Biopharmaceuticals brought in $3.9 billion for 302 deals while 290 medical device deals raised $3.3 billion. In the third quarter device deals raised more than drugs for the first time since 1998, CMIO reports. Five Star Equities examines the outlook for companies in the Medical Equipment & Supplies industry and provides equity research on Medtronic Inc. (NYSE: [ MDT ]) and Guided Therapeutics Inc. (OTCBB: [ GTHP ]). Access to the full company reports can be found at:

[ www.fivestarequities.com/MDT ]
[ www.fivestarequities.com/GTHP ]

Medtronic manufactures and sells device-based medical therapies. It operates in two segments: Cardiac and Vascular Group which includes, Cardiac Rhythm Disease Management, CardioVascular, Physio-Control, and Restorative Therapies Group which include Spinal, Neuromodulation, Diabetes, Surgical Technologies. Earlier this week a federal judge ruled 2 Johnson & Johnson stent patents invalid. The ruling handed a win to Medtronic the latest round of an ongoing legal dispute over drug-eluting stent technology. According to Mass Device Medtronic's Endeavor stent is coated in zotarolimus. Both everolimus and zotarolimus are made by modifying the sirolimus molecule at a single location. J&J and Wyeth claimed that the Endeavor stent was using related drugs without permission.

Five Star Equities releases regular market updates on the Medical Equipment & Supplies industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at [ www.fivestarequities.com ] and get exclusive access to our numerous stock reports and industry newsletters.

Guided Therapeutics, Inc., a medical technology company, engages in developing and providing products for the non-invasive cervical cancer detection markets in the United States and internationally. Earlier this week the company announced that it has submitted the application for CE Mark approval for its LuViva Advanced Cervical Scan. The CE Mark is required to market LuViva in the 27 nations that comprise the European Union (EU).

LuViva is a technologically advanced diagnostic device that scans the cervix with light and uses spectroscopy to measure how light interacts with the cervical tissue. Last month the company announced that LuViva received Health Canada marketing approval on December 14, 2011.

Five Star Equities provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at:
[ www.fivestarequities.com/disclaimer ]